24/7 Market News Snapshot 24 February, 2025 – PepGen Inc. Common Stock (NASDAQ:PEPG)

February 24, 2025

DENVER, Colo., 24 February, 2025 (247marketnews.com) – (NASDAQ:PEPG) are discussed in this article.
PepGen Inc. has recently captured significant attention in the financial markets, with its stock price reaching $1.790, marking an impressive 30.66% surge from the previous close. This sharp rise is underscored by a robust trading volume of 823.27K, reflecting strong investor confidence in the company’s prospects.

The surge in stock performance coincides with the announcement of promising initial results from the ongoing FREEDOM-DM1 Phase 1 clinical trial. This study assesses PepGen’s investigational therapy, PGN-EDODM1, aimed at treating myotonic dystrophy type 1 (DM1). In the 5 mg/kg and 10 mg/kg dose cohorts, the therapy demonstrated remarkable mean splicing corrections of 12.3% and an impressive 29.1%, respectively, at 28 days post-administration. These outcomes signify a notable advancement in addressing the mis-splicing of RNA, a central issue in DM1 pathology.

James McArthur, PhD, President and CEO of PepGen, expressed enthusiasm over these results, noting that the observed mean splicing corrections surpass those reported in previous multi-dose trials extending up to nine months. He emphasized that the trial has also exhibited a favorable safety profile, with the majority of treatment-emergent adverse events classified as mild to moderate, and importantly, no adverse events related to renal biomarkers or electrolyte imbalances were recorded.

As the trial progresses, PepGen anticipates using the results to inform further studies, including the upcoming FREEDOM2-DM1 multiple ascending dose trial. The company plans to release additional data from the 15 mg/kg cohort in late 2025, aiming for initial results from the FREEDOM2 study in early 2026. This forward momentum presents a significant opportunity for PepGen to contribute meaningfully to the treatment landscape for DM1, potentially benefitting patients and families facing this challenging condition.

Related news for (PEPG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.